Aim: To describe the prevalence of diabetic retinopathy (DR) in patients at first presentation for diabetic retinal screening in the greater Wellington region with the intent of service evaluation.
Methods: This is a retrospective study using data collected from patients newly referred for diabetic retinal screening between 2006-2015 (prevalence analysis, n=12667). The prevalence of DR was calculated by gender, ethnicity, age, type of diabetes and glycaemic control (HbA1c). Chi-square test and multiple logistic regression was used for data analysis.
Results: The prevalence of any DR was 22.5% (n=2852) (non-sight-threatening (NST-DR) n=2562, 20.2%, sight-threatening (ST-DR) n=290, 2.3%). Type 1 diabetes and poor HbA1c control were strongly associated with any degree of DR. Old-age (>65 years), and Asian and Pacific Island (PI) ethnicity had moderately greater odds compared with European. Male gender had marginally increased odds for any DR.
Conclusion: This study identified a large proportion (97.7%) of patients (no DR n=9815, 77.5%, NST-DR n=2562, 20.2%) who can be managed in the community by appropriately supported primary care providers, and do not require referral to secondary care ophthalmology. In addition to early detection of ST-DR (2.3%), retinal screening is an early opportunity for education of patients with no DR or NST-DR.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of COVID-19 and recovery of routine diabetic retinopathy digital screening across different regions in England: an analysis of publicly available data.
BMJ Open
December 2024
Vision and Eye Research Institute, School of Medicine, Anglia Ruskin University, Cambridge, UK.
Objective: This study aims to examine the reduction and subsequent recovery of routine digital screening (RDS) uptake in England from 2018 to 2022, exploring national, regional and individual Diabetic Eye Screening Programme (DESP) levels. The COVID-19 lockdown in most areas of England was from 26 March 2020 to 23 June 2020 (first national lockdown), 5 November 2020 to 2 December 2020 (second national lockdown) and 6 January 2021 to 8 March 2021 (third national lockdown).
Design: Retrospective data analysis.
[Peripapillary pachychoroid syndrome].
Vestn Oftalmol
December 2024
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Peripapillary pachychoroid syndrome (PPS) is a recently described condition, classified within the pachychoroid disease spectrum characterized by focal or diffuse thickening of the choroid due to dilation of choroidal vessels in the Haller's layer (pachyvessels), thinning of the choriocapillaris and the Sattler's layer, and accompanied by increased choroidal permeability and damage to the retinal pigment epithelium. Unlike other pachychoroid diseases that involve changes in the central retina, PPS presents with choroidal thickening and intra- or subretinal fluid located nasally in the macular region, near the optic disc. This review aims to summarize and analyze current data on the clinical features, pathogenesis, and treatment options for PPS found in the literature.
View Article and Find Full Text PDFThis article presents a clinical case of ocular thrombotic microangiopathy of mixed origin (antiphospholipid syndrome, malignant arterial hypertension, multigenic thrombophilia). Multimodal imaging of the fundus provides a detailed assessment of its structures. Pathological changes in the choroid, the "retinal pigment epithelium - Bruch's membrane" complex, and the neurosensory retina, identified using fundus photography, short-wavelength autofluorescence, optical coherence tomography (OCT), and OCT angiography, are described as nonspecific in nature.
View Article and Find Full Text PDFUnlabelled: Diabetic macular edema (DME) is a leading cause of visual impairment and blindness among diabetic patients, its prevalence is continuing to increase worldwide. Faricimab, a bispecific antibody, represents a new generation of treatments for DME.
Purpose: This study presents an indirect comparison of the effectiveness and safety of faricimab versus other treatment options for DME.
Purpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!